Anti-Cathepsin W Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the propeptide domain of human Cathepsin W (CTSW, UniProt P56202), validated for Western blot applications.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog, Cat
UniProt
P56202
Size
100ug
Cat. #
RP2CathepsinW

In stock

SKU
RP-CathepsinW

Options

As low as: $130.00

Target Overview

Cathepsin W (CTSW, UniProt P56202) is a cysteine protease (EC 3.4.22.-) belonging to the papain superfamily of proteolytic enzymes. Also known as lymphopain, Cathepsin W is predominantly expressed in CD8+ cytotoxic T lymphocytes and natural killer cells, with localization to the endoplasmic reticulum. The 376-amino acid protein is synthesized as a zymogen with an N-terminal propeptide that requires proteolytic processing for activation. Unlike most cathepsins that exhibit broad tissue distribution, CTSW shows highly restricted expression in immune effector cells, suggesting a specialized role in lymphocyte biology. UniProt functional annotations indicate that Cathepsin W may have a specific function in the mechanism or regulation of T-cell cytolytic activity, though its precise substrates and regulatory mechanisms remain areas of active investigation. Researchers study CTSW in the context of adaptive immunity, tumor immunology, and hematologic malignancies where cytotoxic lymphocyte function is central to disease pathogenesis or therapeutic response.

Background

Cathepsin W is expressed preferentially in cells of the immune system with cytolytic capacity, including CD8+ T cells, NK cells, and certain subsets of cutaneous T-cell lymphomas. Single-cell RNA sequencing has revealed distinct CTSW expression patterns across lymphocyte subsets, with elevated expression correlating with cytotoxic phenotypes in both normal and malignant T-cell populations (Chennareddy et al., 2025). The restricted expression pattern distinguishes CTSW from ubiquitously expressed family members such as cathepsins B, L, and D, and points to a non-redundant role in immune cell function. Recent multi-omics investigations have identified CTSW as a prognostic marker and immunomodulatory factor in solid tumors. In breast cancer, integrated genomic and transcriptomic analyses demonstrated that CTSW expression correlates with immune infiltration signatures and patient outcomes, suggesting that cathepsin W-expressing tumor-infiltrating lymphocytes contribute to anti-tumor immunity (Liu et al., 2025). Similarly, transcriptomic profiling in lung adenocarcinoma has implicated CTSW in programmed cell death pathways within the tumor microenvironment (Yu et al., 2025). These studies position CTSW not only as a marker of cytotoxic lymphocyte presence but also as a potential functional contributor to immune-mediated tumor control. Beyond oncology, CTSW has emerged in neuroimmunology contexts, with transcriptomic analyses of epilepsy identifying altered CTSW expression in immune-related pathways associated with seizure disorders (Li et al., 2025). The molecular mechanisms by which Cathepsin W regulates T-cell cytotoxicity, including identification of physiological substrates and endogenous inhibitors, remain important open questions in the field.

References

  1. Liu X et al (2025) Multi-omics analysis reveals the prognostic value and immunomodulatory role of CTSW in breast cancer. Discov Oncol. PubMed · 10.1007/s12672-025-03550-8
  2. Chennareddy S et al (2025) Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor γδ+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes. Br J Dermatol. PubMed · 10.1093/bjd/ljae313
  3. Li S et al (2025) Integrated Transcriptomic Analysis Provided Diagnostic and Pathophysiological Insights for Epilepsy. J Immunol Res. PubMed · 10.1155/jimr/5925485
  4. Yu P et al (2025) Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification. Sci Rep. PubMed · 10.1038/s41598-025-87982-w

Additional Specifications

Gene Symbol CTSW
UniProt ID P56202
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog, Cat
Pack Size 100ug
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 22-127.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 128-376.
Alternate Names CTSW, Cathepsin W, Lymphopain, EC 3.4.22.-

Frequently Asked Questions

What molecular weight should I expect for Cathepsin W on a Western blot?

Cathepsin W migrates at approximately 42 kDa on reducing SDS-PAGE, corresponding to the full-length 376-amino acid zymogen. Because CTSW is synthesized with an N-terminal propeptide that undergoes proteolytic processing for activation, you may also observe lower molecular weight bands around 28-32 kDa representing the mature, processed form. The band pattern depends on your sample type: CD8+ T cells or NK cell lysates enriched for CTSW often show both pro- and mature forms, whereas samples with lower expression may show only the zymogen. Running a positive control lysate from activated cytotoxic lymphocytes helps distinguish specific signal from background.

Is this antibody validated for mouse Cathepsin W or only human?

This antibody has been validated with human samples. Mouse and rat cross-reactivity are predicted based on epitope homology but have not been experimentally confirmed in our hands. Human and mouse CTSW share approximately 78% sequence identity, so cross-reactivity is plausible, particularly if the epitope falls within a conserved region. If you are working with mouse samples, we recommend titrating the antibody starting at the 1:1000 dilution used for human, running a known-positive control such as activated mouse splenocytes or an NK cell line, and including a blocking peptide control if available to confirm specificity.

What positive control cell type should I use for Cathepsin W Western blots?

CD8+ cytotoxic T lymphocytes and natural killer cells are the most reliable positive controls, as CTSW expression is highly restricted to these immune effector populations. Activated human PBMCs, particularly after stimulation with IL-2 or anti-CD3/CD28, show robust CTSW expression. NK cell lines such as NK-92 or YT cells are also suitable. Negative controls should include non-lymphoid tissues or CD4+ T cells, which express little to no Cathepsin W. Whole spleen or lymph node lysates may show weak signal due to dilution by non-expressing cell types, so enriched lymphocyte populations yield clearer results.

Can I use this antibody for immunofluorescence to see Cathepsin W localization?

Yes, Triple Point antibodies are validated for immunofluorescence as well as Western blot and IHC. Given that Cathepsin W localizes primarily to the endoplasmic reticulum in resting cells, you should see a perinuclear reticular staining pattern in positive cells. In activated cytotoxic lymphocytes, CTSW may redistribute to secretory lysosomes or granules. Start with a 1:100 to 1:200 dilution for IF, as this is typically less sensitive than Western blot. Permeabilization is essential since CTSW is intracellular. Co-staining with an ER marker such as calnexin or PDI can help confirm the expected subcellular distribution in your system.

What dilution should I start with for Western blot of Cathepsin W?

We recommend starting at 1:1000 for Western blot, which has been validated with this antibody. This dilution typically provides clean signal with low background when using 20-30 µg of total protein from CTSW-expressing cell lysates. If your sample has low expression or you are working with whole tissue homogenates rather than purified lymphocytes, you may need to use a more concentrated dilution such as 1:500. Conversely, if background is high, titrate up to 1:2000. Blocking in 5% non-fat milk or BSA in TBST for one hour at room temperature works well for this rabbit polyclonal.

Does Cathepsin W have splice isoforms I need to account for?

UniProt lists a single canonical isoform for human Cathepsin W (P56202-1), and no functionally distinct splice variants have been well characterized in the literature. You should expect one major band corresponding to the 376-amino acid zymogen at approximately 42 kDa, plus possible lower molecular weight bands representing proteolytically processed mature forms. If you observe multiple high molecular weight bands, consider post-translational modifications such as glycosylation, which can affect migration. Unlike some cathepsins with tissue-specific variants, CTSW appears to be expressed as a single predominant form in cytotoxic lymphocytes, simplifying interpretation of Western blot and IHC data.

How should I store this antibody and how long will it remain stable?

Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The 100 µg pack size is suitable for dividing into 10-20 µL aliquots depending on your planned experiments. Once thawed, an aliquot can be stored at 4°C with 0.02% sodium azide for up to one month for convenience during active experiments. Avoid prolonged storage in frost-free freezers due to temperature cycling. Properly stored aliquots typically retain activity for at least two years from the manufacture date. If you notice increased background or reduced signal over time, prepare a fresh aliquot rather than re-using older working stocks.

Why do I see low or no signal for Cathepsin W in my samples?

Cathepsin W has extremely restricted expression, limited almost exclusively to CD8+ T cells and NK cells. If you are using whole tissue lysates, unfractionated PBMCs, or non-lymphoid cell lines, CTSW protein may be below the detection threshold. Verify that your sample contains cytotoxic lymphocytes and consider enriching CD8+ or NK populations by magnetic sorting or density gradient. CTSW expression is also upregulated upon activation, so resting cells may show weak signal. Running a validated positive control such as activated NK-92 cells or IL-2-stimulated PBMCs in parallel confirms that the antibody is working and helps distinguish true absence from technical failure.

Western blot validation for RP-CathepsinW — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Cathepsin-W: Propeptide domain — WB validation
WB · Panel 1 Cathepsin-W: Propeptide domain
Cathepsin-W: Catalytic domain — WB validation
WB · Panel 2 Cathepsin-W: Catalytic domain

Custom validation studies available on request — contact us.

Also known as:

  • CTSW
  • Cathepsin W
  • Lymphopain
  • EC 3.4.22.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →